Colchicine for Acute Coronary Syndromes

Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial.

Multicenter, double blind, randomized trial to assess the effect of low-dose colchicine (0.5mg/day) on overall mortality, new coronary syndromes, and ischemic stroke at 2 years after an acute coronary syndrome. The study hypothesis is that colchicine may reduce the specified combined endpoint from 16% to 7-8% at a 2-years follow-up.

Multicenter, double-blind randomized trial to evaluate the efficacy of low dose colchicine (0.5mg once daily for 2 years) to reduce the incidence of subsequent overall mortality, new acute coronary syndromes, and ischemic stroke in patients admitted for an acute coronary syndrome.

Inclusion Criteria:

• >18years
• Acute coronary syndrome (unstable angina or acute myocardial infarction)
• Life expectancy> 2 years
• Absence of contraindications to colchicine

Exclusion Criteria:

• Colchicine treatment for any cause
• Severe liver disease
• Renal insufficiency with creatinine>150mmol/l or creatinine clearance<30ml/min/1.73m2
• Known cancer
• Chronic inflammatory bowel disease
• treatment with cyclosporine
• allergy or hypersensitivity to colchicine
• pregnancy or lactating woman or woman with childbearing potential without valid contraception